Drug Profile
GSK 3368715
Alternative Names: GSK3368715Latest Information Update: 22 Aug 2022
Price :
$50
*
At a glance
- Originator Epizyme
- Developer GSK
- Class Antineoplastics
- Mechanism of Action Protein arginine N methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diffuse large B cell lymphoma; Solid tumours
Most Recent Events
- 12 Aug 2022 Epizyme has been acquired by Ipsen
- 01 Jun 2022 GlaxoSmithKline terminates a phase I trial in Solid tumours and Diffuse large B cell lymphoma (Inoperable/Unresectable, Metastatic disease) in USA, Australia, Canada and Spain (PO) due to overall benefit-risk profile which did not support the continuation of the study (EudraCT2018-001629-20) (NCT03666988)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Inoperable/Unresectable, Metastatic disease) in Australia (PO, Capsule)